Tatyana Y Doktorova
Overview
Explore the profile of Tatyana Y Doktorova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Aubrecht J, Doktorova T, Jennen D, Corton J, Froetschl R, et al.
Environ Mol Mutagen
. 2025 Mar;
PMID: 40035370
The current genotoxicity testing paradigm provides little mechanistic information, has poor specificity in predicting carcinogenicity in humans, and is not suited to assessing a large number of chemicals. Genomic technologies...
2.
Froetschl R, Corton J, Li H, Aubrecht J, Auerbach S, Caiment F, et al.
Environ Mol Mutagen
. 2025 Jan;
PMID: 39757731
Gene expression biomarkers have the potential to identify genotoxic and non-genotoxic carcinogens, providing opportunities for integrated testing and reducing animal use. In August 2022, an International Workshops on Genotoxicity Testing...
3.
Doktorova T, Azzi P, Hofer J, Messner C, Gaiser C, Werner S, et al.
Altern Lab Anim
. 2022 Feb;
50(1):71-75.
PMID: 35179997
The need to reduce, refine and replace animal experimentation has led to a boom in the establishment of new approach methodologies (NAMs). This promising trend brings the hope that the...
4.
Doktorova T, Oki N, Mohoric T, Exner T, Hardy B
Regul Toxicol Pharmacol
. 2020 Apr;
114:104652.
PMID: 32251711
The utility of the Adverse Outcome Pathway (AOP) concept has been largely recognized by scientists, however, the AOP generation is still mainly done manually by screening through evidence and extracting...
5.
Oki N, Farcal L, Abdelaziz A, Florean O, Doktorova T, Exner T, et al.
Toxicol In Vitro
. 2018 Sep;
54:23-32.
PMID: 30196099
The integration of existing knowledge to support the risk assessment of chemicals is an ongoing challenge for scientists, risk assessors and risk managers. In addition, European Union regulations limiting the...
6.
Ates G, Mertens B, Heymans A, Verschaeve L, Milushev D, Vanparys P, et al.
Arch Toxicol
. 2018 Feb;
92(4):1593-1608.
PMID: 29411056
Although the value of the regulatory accepted batteries for in vitro genotoxicity testing is recognized, they result in a high number of false positives. This has a major impact on...
7.
Ates G, Favyts D, Hendriks G, Derr R, Mertens B, Verschaeve L, et al.
Mutat Res Genet Toxicol Environ Mutagen
. 2016 Oct;
810:13-21.
PMID: 27776687
To ensure safety for humans, it is essential to characterize the genotoxic potential of new chemical entities, such as pharmaceutical and cosmetic substances. In a first tier, a battery of...
8.
Ates G, Raitano G, Heymans A, Van Bossuyt M, Vanparys P, Mertens B, et al.
Mutagenesis
. 2016 Mar;
31(4):453-61.
PMID: 26980085
Prior to the downstream development of chemical substances, including pharmaceuticals and cosmetics, their influence on the genetic apparatus has to be tested. Several in vitro and in vivo assays have...
9.
Rodrigues R, Kock J, Doktorova T, Rogiers V, Vanhaecke T
Methods Mol Biol
. 2015 Aug;
1250:279-85.
PMID: 26272150
Cytochrome P450 enzymes are a diverse group of catalytic enzymes in the liver that are mainly responsible for the biotransformation of organic substances. Cytochrome P450 activity as well as both...
10.
Ates G, Doktorova T, Pauwels M, Rogiers V
Mutagenesis
. 2014 Jan;
29(2):115-21.
PMID: 24435663
To evaluate the mutagenicity/genotoxicity of cosmetic ingredients at the regulatory level, usually a battery of three in vitro tests is applied. This battery, designed to be very sensitive, produces a...